Evidence map›Paper›PMID 31239655›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2019

Sputum

Leena George, Adam Wright, Vijay Mistry, Amanda Sutcliffe, Latifa Chachi, Koirobi Haldar, Mohammadali Yavari Ramsheh, Matthew Richardson, René van der Merwe, Ubaldo Martin and 2 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Leena GeorgeDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Adam WrightDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Vijay MistryDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Amanda SutcliffeDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Latifa ChachiDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Koirobi HaldarDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Mohammadali Yavari RamshehDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Matthew RichardsonDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
René van der MerweClinical Respiratory Management, MedImmune Ltd., Cambridge, UK.
Ubaldo MartinGlobal Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Paul NewboldGlobal Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Christopher E BrightlingDepartment of Respiratory Sciences, Institute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
University of Leicester · GBAstraZeneca (United States) · USAimmune Therapeutics (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and

Indexed as

Antibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsBacterial LoadHumansLungPulmonary Disease, Chronic ObstructiveRibotypingSputumStreptococcus pneumoniaeTime FactorsTreatment OutcomeAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agentsbenralizumabbacterial loadbenralizumabCOPDH. influenzaeIL-5S. pneumoniae

Identifiers

PMID31239655
PMCPMC6559763
OpenAlexW2948921314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.